-
Kombiglyze XR now available
PRINCETON, N.J. — A new oral treatment for Type 2 diabetes hit the shelves Friday.
Bristol-Myers Squibb and AstraZeneca announced the availability of Kombiglyze XR (saxagliptin and metformin hydrochloride), which the companies called the only once-daily treatment for diabetes that combined metformin with a DPP-4 inhibitor, the drug class to which saxagliptin belongs.
The drug is designed for use alongside diet and exercise to improve glycemic control in adults with Type 2 diabetes.
-
Adherence among chronic disease patients can lead to big savings
WOONSOCKET, R.I. — Patients with one or more out of four chronic diseases studied who take their medications as prescribed may save the healthcare system as much as $7,800 per patient annually, according to findings of a new CVS Caremark study analyzing annual pharmacy and medical costs over a three-year period.